Medical Library | Shanghai Clinical Innovation Series
Fudan University Huashan Hospital is one of Shanghai's leading centers for neurology, neurosurgery, infectious disease, dermatology, rehabilitation, and translational medicine. Its 2025–2026 programs span stroke emergency systems, blood biomarkers for Alzheimer's disease, alpha-synuclein imaging, implantable brain–computer interfaces, cerebrovascular surgery, rapid pathogen identification, new dermatology medicines, and neurorehabilitation.
This Medical Library review summarizes eight representative teams and directions based on the information provided. It also explains how international patients can prepare for specialist consultations and evaluate whether a new diagnostic tool, device, medicine, or rehabilitation strategy is appropriate.
1. Cerebrovascular Neurology: Emergency Stroke Systems, Antithrombotic Therapy, and Biomarkers
Lead: Professor Dong Qiang
Focus: Stroke, endovascular treatment, antithrombotic therapy, and vascular cognitive impairment.
The program combines three parts of modern stroke care: rapid emergency access, new antithrombotic strategies, and biological markers that may improve diagnosis or risk assessment. The supplied information describes the “Shanghai Stroke Emergency Map” as covering 57 institutions, creating a regional network for faster referral and treatment.
Key 2025–2026 milestones
- c-BEEVs: Brain vascular endothelial cell-derived extracellular vesicle markers were reported in Nature Aging in May 2026.
- OCEANIC-STROKE: The role of an FXIa inhibitor was reviewed in April 2026, reflecting interest in anticoagulation strategies that may reduce thrombosis while limiting bleeding risk.
- Emergency coordination: The Shanghai stroke emergency map was reported as a verified regional-system achievement.
For patients and families, a stroke network matters because time to imaging, thrombolysis, thrombectomy, intensive care, and secondary prevention can affect outcomes. Patients should ask which hospital is responsible for each stage of care and how transfer decisions are made.
The c-BEEV findings are an early biomarker direction rather than a replacement for clinical examination, brain imaging, vascular imaging, or standard laboratory tests. Patients considering new antithrombotic therapy should discuss stroke mechanism, atrial fibrillation, bleeding risk, kidney function, previous hemorrhage, and interactions with other medicines.
Our Stroke Prevention and Brain Health Management guide provides related background for international patients.
Clinical profile: A three-part stroke platform linking emergency coordination, antithrombotic research, and biomarker development.
2. Alzheimer's Disease: Blood Proteomics, Plasma p-tau217, and Tau-PET
Lead: Professor Yu Jintai
Focus: Early Alzheimer's screening, biomarkers, and precision classification.
Alzheimer's disease research is moving toward earlier and more biologically specific diagnosis. The Huashan program is described as being at the forefront of translating blood biomarkers into clinical practice.
Key 2025–2026 milestones
- Blood proteomics: A plasma protein atlas described as a “one-drop-of-blood” approach to predicting Alzheimer's disease was featured in Cell in January 2025. The supplied information reports a combined diagnostic accuracy of 98.7%.
- Plasma p-tau217: Real-world validation was reported in July 2026.
- Tau-PET: Additional data reported in July 2026 examined how tau-PET may improve diagnostic performance.
Blood biomarkers may eventually make screening and monitoring more accessible, but test performance can vary according to the population, disease stage, laboratory method, and reference standard. A positive biomarker does not by itself determine a person's future cognitive course or prove that a specific treatment will work.
Patients should ask what the test measures, whether it has been clinically validated, how results are reported, whether confirmatory imaging or cerebrospinal-fluid testing is needed, and how the result would change treatment or care planning. Our related Huashan Hospital Alzheimer's disease and cognitive disorders specialist profile may help families prepare for a consultation.
Clinical profile: A biomarker-translation program connecting plasma proteomics, p-tau217, PET imaging, and precision diagnosis.
3. Movement Disorders: Alpha-Synuclein PET and Fluid Biomarkers for Parkinson's Disease
Team: A collaboration between Huashan Hospital, the Chinese Academy of Sciences team led by Liu Cong, and Sinovex Bio
Focus: Early Parkinson's disease diagnosis and differentiation from multiple-system atrophy.
Parkinson's disease and multiple-system atrophy can share symptoms while requiring different prognostic counseling and treatment planning. Biomarkers that detect or track alpha-synuclein may help clinicians identify disease biology earlier than symptoms alone.
Key 2025–2026 milestones
- SST001: An alpha-synuclein PET tracer Phase I study began in June 2026. It was described as China's first registered clinical alpha-synuclein PET program.
- TPPP/p25-SAA: A fluid-based testing approach was reported in Cell in June 2026.
These programs represent two complementary strategies: PET imaging to visualize disease-related biology and fluid testing to identify molecular signals through blood or other body fluids. Neither approach should be treated as a universal diagnostic replacement until accuracy, reproducibility, and clinical usefulness are established across diverse patients.
Patients should ask whether a test is available only through a clinical trial, whether it can distinguish Parkinson's disease from multiple-system atrophy in routine practice, and whether the result changes medication, rehabilitation, genetic counseling, or follow-up.
For related patient education, see our Parkinson's disease and movement disorders guide.
Clinical profile: A dual-track early-diagnosis program combining alpha-synuclein PET imaging with fluid biomarker testing.
4. Neurosurgery and Brain–Computer Interfaces: Moving from Research to Clinical Translation
Lead: Professor Mao Ying, President of Huashan Hospital
Focus: Brain–computer interfaces, deep-brain stimulation for Parkinson's disease, and epilepsy surgery.
The supplied information states that the NEO implantable brain–computer interface received approval for marketing on March 13, 2026, and was described as the world's first approved implantable BCI Class III medical device. Validation reportedly involved 11 centers and 32 cases, followed by the first reported implantation surgery in July 2026.
Implantable BCI systems aim to record or stimulate neural signals so that patients may control an external device, communicate, or participate in rehabilitation. The field remains highly specialized. Approval status, intended use, patient eligibility, surgical risk, device programming, infection prevention, and long-term maintenance all need to be confirmed directly with the treating center.
Our Brain–Computer Interface Therapy in Shanghai guide provides additional patient-oriented background. Patients should also ask whether the device is approved for communication, motor control, rehabilitation, or another specific use, because “BCI approval” does not mean that every application is clinically available.
Clinical profile: A neurosurgical program positioned at the front line of implantable BCI translation, alongside DBS and epilepsy surgery.
5. Cerebrovascular Neurosurgery: A Multimodal System for Moyamoya Disease
Lead: Professor Gu Yuxiang
Focus: Moyamoya disease, cerebral aneurysms, arteriovenous malformations, and vascular bypass surgery.
The team is reported to have received the First Prize of the 2026 Shanghai Medical Science and Technology Award for a multimodal diagnostic and treatment system for moyamoya disease. It is also reported to perform more than 1,000 bypass operations annually, with FLOW800 used in more than 80% of cases.
Moyamoya disease requires individualized evaluation of cerebral blood flow, collateral vessels, ischemic symptoms, hemorrhage risk, age, and the pattern of vessel narrowing. Bypass surgery can improve blood supply in selected patients, while FLOW800 and other intraoperative tools may help surgeons assess perfusion during the procedure.
Patients should ask what imaging is needed, whether direct bypass, indirect bypass, or a combined approach is recommended, how the risk of hyperperfusion will be managed, and what long-term imaging schedule is planned.
Clinical profile: A high-volume East Asian cerebrovascular program combining multimodal assessment, bypass surgery, and intraoperative perfusion guidance.
6. Infectious Disease: Rapid Diagnosis, Resistance Surveillance, and Emerging Threats
Lead: Professor Zhang Wenhong
Focus: Drug-resistant tuberculosis, antiviral resistance, sepsis, and emerging infectious diseases.
Key 2025–2026 milestones
- PROGRESS: A digital PCR strategy reported in Nature Communications in August 2026 was described as identifying the causative pathogen in sepsis within 6.6 hours.
- Baloxavir resistance surveillance: Real-world monitoring reported in January 2026 covered nearly 4,000 cases and found no I38X resistance in the supplied dataset.
- Shorter drug-resistant tuberculosis treatment: The September 2026 discussion focused on the possibility of shorter treatment regimens for drug-resistant TB.
Rapid pathogen identification can be clinically valuable because broad empiric antibiotics may be narrowed or changed once the cause is known. The result must still be interpreted with cultures, imaging, clinical examination, immune status, and local resistance patterns.
Resistance monitoring is also population-specific. The absence of a resistance mutation in one surveillance group does not mean that resistance is impossible in an individual patient. Patients should not start, stop, or change antiviral or antibiotic treatment without specialist advice.
Our Infectious Disease at Huashan Hospital article provides related information for international patients.
Clinical profile: A public-health and clinical platform linking rapid molecular diagnosis with resistance surveillance and emerging-infection preparedness.
7. Dermatology: Expanding Evidence-Based Treatment for Psoriasis and Atopic Dermatitis
Lead: Professor Xu Jinhua
Focus: Psoriasis, atopic dermatitis, and autoimmune skin disease.
Key 2025–2026 milestones
- An IL-17A monoclonal antibody identified in the source material as Gumuqi received NMPA approval in June 2026, with reported PASI 100 results described as highly competitive within its class.
- An antibody identified in the source material as Anmuqita received approval and was used for its first prescription in China.
- SHR-1819 entered or reported Phase II development, with data published in BMC Medicine in July 2026.
- ICP-332 Phase II data were published in JAMA Dermatology in January 2026.
Because product transliterations can vary across countries, patients should confirm the generic name, target, approved indication, dosing schedule, and regulatory label directly with the treating dermatologist. PASI 100 means complete skin clearance according to a defined scoring system, but response durability, joint symptoms, infection risk, pregnancy considerations, and cost also matter.
Our Psoriasis and Skin Disorders Treatment in Shanghai Medical Library guide provides additional background.
Clinical profile: A leading dermatology clinical-trial platform bringing new biologics and small molecules into treatment for immune-mediated skin disease.
8. Rehabilitation Medicine: Spinal Stimulation, Motor-Imagery BCI, and Stroke Recovery
Leads: Professors Wu Yi, Zhu Yulian, and Sun Bing
Focus: Post-stroke rehabilitation, spinal-cord injury, and neuromodulation.
The program is reported to have contributed to a July 2026 expert consensus on spinal cord stimulation for post-stroke hemiplegia. Other reported progress includes a 70% effectiveness rate for neuromodulation in December 2025 and motor-imagery BCI training in 2026.
Rehabilitation outcomes depend on stroke location, severity, time since injury, cognition, spasticity, strength, sensation, motivation, sleep, and the intensity of therapy. Neuromodulation and BCI may be useful for selected patients, but “effectiveness” should be interpreted according to the study's endpoint, comparison group, follow-up duration, and patient population.
Patients should ask whether the intervention is approved or part of a research program, what functional outcome is expected, how many sessions are needed, and how the treatment will be combined with conventional physical, occupational, and speech therapy.
Clinical profile: A rehabilitation program integrating neuromodulation, BCI-based motor training, and structured recovery after stroke or spinal-cord injury.
9. How CMCS Helps International Patients Communicate with Specialists
For an international patient considering neurology, neurosurgery, infectious-disease, dermatology, or rehabilitation care in Shanghai, the first step is to match the clinical question with the right specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a consultation, CMCS can help organize brain imaging, vascular imaging, PET or biomarker reports, neuropsychological testing, pathology, infection tests, drug-resistance results, skin photographs, biopsy reports, rehabilitation records, medication history, and current symptoms. For overseas patients, the information can be arranged into a concise English medical summary for the specialist.
CMCS can help patients prepare focused questions such as:
- Is the proposed biomarker, PET tracer, BCI device, medicine, or rehabilitation intervention clinically validated and available for this indication?
- Does the patient meet the exact eligibility criteria for the proposed clinical trial or procedure?
- What alternative standard treatments or rehabilitation options should be considered?
- What are the major surgical, infectious, neurological, dermatological, or device-related risks?
- How will response, cognition, motor function, infection, drug resistance, skin clearance, or device performance be monitored?
- What follow-up, maintenance, medication, rehabilitation, and caregiver support will be required?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient and the treating medical team. CMCS does not independently select a drug, device, clinical trial, surgery, or rehabilitation program. Its role is to help the patient bring complete information to the right specialist and ensure that evidence, eligibility, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about specialist consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
The Huashan Hospital teams reviewed here show how clinical innovation is expanding across emergency systems, blood biomarkers, molecular imaging, implantable neurotechnology, cerebrovascular surgery, rapid infectious-disease diagnosis, dermatology medicines, and rehabilitation.
For patients, the most useful next step is not to pursue every new technology, but to determine which evidence-based option fits the diagnosis, stage, biomarker profile, disability, health status, and personal goals. This article was prepared from the team and program information provided for editorial use. Research findings, approval status, product names, clinical claims, and treatment availability should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 commentaire